CLINICAL_TRIALS
trial_result
· 2019-01-18
Clinical Trial Update: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients [Phase 1]
Summary
Phase 1 study evaluating ascending single doses of erenumab (AMG 334) in healthy adults and migraine patients. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2019-01-18